(Q46406537)

21 December 2017

title

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia (English)

1 reference

21 December 2017

1 reference

M Paganin

1

1 reference

21 December 2017

M Zecca

2

1 reference

21 December 2017

G Fabbri

3

1 reference

21 December 2017

K Polato

4

1 reference

21 December 2017

A Biondi

5

1 reference

21 December 2017

C Rizzari

6

1 reference

21 December 2017

F Locatelli

7

1 reference

21 December 2017

G Basso

8

1 reference

21 December 2017

publication date

28 August 2008

1 reference

21 December 2017

published in

Leukemia

1 reference

21 December 2017

volume

22

1 reference

21 December 2017

issue

12

1 reference

21 December 2017

page(s)

2193-2200

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.227

exact match

0 references

cites work

Treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

A second course of treatment for childhood acute lymphoblastic leukaemia: long-term follow-up is needed to assess results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.227

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.227

1 reference

21 December 2017

1 reference

21 December 2017